Relationship Between Final Height and Health Outcomes in Adults With Congenital Adrenal Hyperplasia: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE)
| Autor: | Debbie S. Willis, Thang S. Han, Aled Rees, Roland Stimson, Wiebke Arlt, Richard S. Ross, Gerard S. Conway, Brian R. Walker, Nils Krone |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Cross-sectional study Endocrinology Diabetes and Metabolism Clinical Biochemistry Population Context (language use) Health outcomes Severity of Illness Index Biochemistry Short stature Cohort Studies Young Adult Endocrinology Risk Factors Internal medicine Severity of illness medicine Humans Congenital adrenal hyperplasia Young adult education education.field_of_study Adrenal Hyperplasia Congenital business.industry Final height Biochemistry (medical) Middle Aged Prognosis medicine.disease Body Height United Kingdom Cross-Sectional Studies Treatment Outcome Cardiovascular Diseases Female medicine.symptom business Cohort study |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 99:E1547-E1555 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jc.2014-1486 |
| Popis: | Treatment of congenital adrenal hyperplasia (CAH) in childhood focuses on growth and development and adult final height (FH) is a measure of effective treatment. We hypothesized that shorter adults will have more severe underlying disease and worse health outcomes.This was a cross-sectional analysis of 199 adults with CAH. FH and quality of life were expressed as z-scores adjusted for midparental target height or UK population height.FH correlated inversely with age (men, r = -0.38; women, r = -0.26, P.01). Men and women had z-scores adjusted for midparental target height of -2 and -1, respectively, and both groups had UK population height z-scores of -1 below the UK population (P.01). In women, FH was shorter in non-salt-wasting than salt-wasting classic CAH (P.05) and in moderately affected genotype group B women than either more severely affected groups null and A (P.01) or the mildest group C (P.001). Short stature and a higher prevalence of hypertension were observed in classic CAH patients diagnosed late (after 1 y) compared with those diagnosed early and in women treated with glucocorticoid only compared with those treated with both glucocorticoids and mineralocorticoids (P.05). FH did not associate with insulin sensitivity, lipid profile, adiposity, or quality of life.Adult CAH patients remain short, although height prognosis has improved over time. The shortest adults are those diagnosed late with moderate severity CAH and are at increased risk of adult hypertension; we hypothesize that these patients are exposed in childhood to high androgens and/or excessive glucocorticoids with potential programming of hypertension. Another possibility is inadequate mineralocorticoid treatment early in life in the late-diagnosed patient group. Prospective studies are now required to examine these hypotheses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|